A nontumorigenic variant of FGF19 treats cholestatic liver diseases

• DOI: 10.1126/scitranslmed.3009098
• Publication Date: 2014-07-30T19:45:17Z
• Authors: Jian Luo; Brian Ko; Michael Elliott; Mei Zhou; Darrin A. Lindhout; Van Phung; Carmen To; R. Marc Learned; Hui Tian; Alex M. DePaoli; Lei Ling
• Keywords: Adult; 0301 basic medicine; Cholagogues and Choleretics; Australia; Gene Transfer Techniques; Down-Regulation; Genetic Variation; Cholestasis, Intrahepatic; Cholestasis, Extrahepatic; Gene Expression Regulation, Enzymologic; Healthy Volunteers; 3. Good health; Bile Acids and Salts; Fibroblast Growth Factors; Disease Models, Animal; 03 medical and health sciences; Double-Blind Method; Liver; Animals; Humans; Cholesterol 7-alpha-Hydroxylase; Biomarkers; Cholestenones

Nontumorigenic FGF19 variants represent an effective approach for the prevention and treatment of cholestatic liver diseases.